Novocure [NVCR] vs Boston Scientific [BSX] Detailed Stock Comparison

Novocure

NASDAQ
Loading...

Boston Scientific

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 19 vital metrics comparison: Novocure wins in 7 metrics, Boston Scientific wins in 11 metrics, with 0 ties. Boston Scientific appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricNovocureBoston ScientificBetter
P/E Ratio (TTM)-9.4057.93Novocure
Price-to-Book Ratio4.696.43Novocure
Debt-to-Equity Ratio200.3953.09Boston Scientific
PEG Ratio-0.580.40Novocure
EV/EBITDA-8.9933.14Novocure
Profit Margin (TTM)-27.13%13.55%Boston Scientific
Operating Margin (TTM)-24.89%18.63%Boston Scientific
EBITDA Margin (TTM)N/A18.63%N/A
Return on Equity-48.07%11.55%Boston Scientific
Return on Assets (TTM)-8.64%5.39%Boston Scientific
Free Cash Flow (TTM)$-69.22M$2.37BBoston Scientific
1-Year Return-0.41%15.12%Boston Scientific
Price-to-Sales Ratio (TTM)2.607.80Novocure
Enterprise Value$1.43B$155.93BBoston Scientific
EV/Revenue Ratio2.278.43Novocure
Gross Profit Margin (TTM)73.88%67.65%Novocure
Revenue per Share (TTM)$6$13Boston Scientific
Earnings per Share (Diluted)$-1.56$1.68Boston Scientific
Beta (Stock Volatility)0.750.61Boston Scientific
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

Novocure vs Boston Scientific Stock Performance Analysis

Loading Price Chart...

Novocure
Boston Scientific
Novocure Stock Overview | Boston Scientific Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Novocure-1.09%13.73%21.36%-17.22%-13.66%-51.12%
Boston Scientific-0.64%-0.88%-9.50%-6.71%-1.20%8.88%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Novocure-0.41%-81.98%-89.43%-30.26%-19.80%-19.80%
Boston Scientific15.12%144.77%136.56%476.54%1,487.60%312.37%

News Based Sentiment: Novocure vs Boston Scientific

Novocure

News based Sentiment: MIXED

Novocure showcased strong clinical trial results and continued revenue growth, but remains unprofitable and faces mixed analyst opinions. The upcoming FDA submissions and Q3 earnings report will be critical catalysts for the stock's performance, creating a mixed investment narrative.

View Novocure News Sentiment Analysis

Boston Scientific

News based Sentiment: POSITIVE

October brought a wave of positive signals for Boston Scientific, including increased institutional investment, raised price targets from multiple firms, and a promising long-range plan. While insider selling remains a point to watch, the overall narrative is one of strong growth potential and investor confidence.

View Boston Scientific News Sentiment Analysis

Performance & Financial Health Analysis: Novocure vs Boston Scientific

MetricNVCRBSX
Market Information
Market Cap i$1.64B$144.20B
Market Cap CategorySmall capLarge cap
10 Day Avg. Volume i2,239,56012,773,240
90 Day Avg. Volume i1,734,68010,174,867
Last Close$14.50$96.70
52 Week Range$10.87 - $34.13$80.64 - $109.50
% from 52W High-57.52%-11.69%
All-Time High$232.76 (Jun 21, 2021)$109.50 (Sep 09, 2025)
% from All-Time High-93.77%-11.69%
Growth Metrics
Quarterly Revenue Growth0.06%0.23%
Quarterly Earnings Growth0.06%1.46%
Financial Health
Profit Margin (TTM) i-0.27%0.14%
Operating Margin (TTM) i-0.25%0.19%
Return on Equity (TTM) i-0.48%0.12%
Debt to Equity (MRQ) i200.3953.09
Cash & Liquidity
Book Value per Share (MRQ)$3.13$15.14
Cash per Share (MRQ)$8.15$0.36
Operating Cash Flow (TTM) i$-44,676,000$4.28B
Levered Free Cash Flow (TTM) i$5.94M$2.94B
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Novocure vs Boston Scientific

MetricNVCRBSX
Price Ratios
P/E Ratio (TTM) i-9.4057.93
Forward P/E i-9.7734.88
PEG Ratio i-0.580.40
Price to Sales (TTM) i2.607.80
Price to Book (MRQ) i4.696.43
Market Capitalization
Market Capitalization i$1.64B$144.20B
Enterprise Value i$1.43B$155.93B
Enterprise Value Metrics
Enterprise to Revenue i2.278.43
Enterprise to EBITDA i-8.9933.14
Risk & Other Metrics
Beta i0.750.61
Book Value per Share (MRQ) i$3.13$15.14

Financial Statements Comparison: Novocure vs Boston Scientific

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)NVCRBSX
Revenue/Sales i$154.99M$4.66B
Cost of Goods Sold i$38.52M$1.45B
Gross Profit i$116.47M$3.21B
Research & Development i$53.78M$443.00M
Operating Income (EBIT) i$-37.87M$937.00M
EBITDA i$-34.54M$1.23B
Pre-Tax Income i$-30.30M$805.00M
Income Tax i$4.02M$133.00M
Net Income (Profit) i$-34.32M$672.00M

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)NVCRBSX
Cash & Equivalents i$127.28M$725.00M
Total Current Assets i$1.09B$7.34B
Total Current Liabilities i$743.31M$5.06B
Long-Term Debt i$137.76M$10.93B
Total Shareholders Equity i$361.96M$22.45B
Retained Earnings i$-1.19B$3.35B
Property, Plant & Equipment i$145.02M$448.00M

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)NVCRBSX
Operating Cash Flow i$-14.80M$513.00M
Capital Expenditures i$-10.61M$-187.00M
Free Cash Flow i$-46.28M$277.00M
Debt Repayment i$0$-1.31B
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricNVCRBSX
Shares Short i5.89M19.02M
Short Ratio i4.332.76
Short % of Float i0.08%0.01%
Average Daily Volume (10 Day) i2,239,56012,773,240
Average Daily Volume (90 Day) i1,734,68010,174,867
Shares Outstanding i108.52M1.47B
Float Shares i94.06M1.48B
% Held by Insiders i0.10%0.00%
% Held by Institutions i0.86%0.94%

Dividend Analysis & Yield Comparison: Novocure vs Boston Scientific

MetricNVCRBSX
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A